Other authors have shown that IAP antagonists may induce high turnover osteoporosis characterized by enhanced osteoclast and osteoblast activities in mice and may increase the risk of tumour growth and metastasis in the bone by stabilizing NF-κB inducing kinase (NIK) and activating the alternative NF-κB pathway in osteoclasts [39]. Here, NFKB1 is linked to neoplasm.